The quest for holistic approaches to treating Inflammatory Bowel Disease (IBD) has become increasingly urgent. Patients worldwide yearn for solutions that not only alleviate symptoms but also personalize their treatment processes. Today, a handful of healthcare startups are underway in pioneering new technologies and therapies aimed at revolutionizing IBD treatment. These startups leverage advanced medical research to develop innovative protocols tailored to individual patient needs.
Taking charge in this movement are the founders of Evinature: Professor Shomron Ben-Horin, M.D., Nir Salomon, and Apan Amos Damri. Their journey from groundbreaking research to the establishment of a pioneering platform has transformed the landscape of IBD treatment, offering hope and relief to patients worldwide.
Evinature is a trailblazing healthcare startup that’s spearheading groundbreaking research in nutraceutical therapies tailored specifically for IBD patients. It is widely revered as the home of the CurQD® Protocol, a set of natural, clinically proven regimens tailored specifically to each individual to address each stage of IBD. This evidence-based therapy integrates natural remedies into standard clinical practice, providing patients with safe and effective alternatives to traditional pharmaceuticals.
Over ten years of research and development, their successful placebo-controlled trial on CurQD® earned the Poster of Distinction at the Crohn’s and Colitis Foundation of America (CCFA). The CurQD® Protocol has since been integrated into top medical centers. Following the trial’s success, Salomon, Ben-Horin, and Damri founded Evinature, aiming to promote safe, clinically validated natural remedies. Evinature’s patient-centered platform offers integrative strategies, guided care from a team of experts, research updates, and essential information to the community.
Professor Shomron Ben-Horin, M.D.
Professor Shomron Ben-Horin, M.D. is the Co-founder of Evinature. He’s also Chief of the Gastroenterology Department & Director of the Gastro-Immunology Research Laboratory at Sheba Medical Center, one of Newsweek’s 10 best hospitals in the world. With over 200 peer-reviewed articles and numerous accolades to his name, including leadership roles in esteemed medical societies, Ben-Horin’s commitment to advancing patient care is unwavering.
His collaboration with integrative expert Nir Salomon paved the way for the development of the CurQD® Protocol, marking a significant milestone in the quest for natural therapies for IBD.
Nir Salomon
Nir Salomon is the Founder & Director of the Integrative Gastroenterology unit at Sheba Medical Center and the Co-founder and Head of R&D at Evinature. His relentless pursuit of evidence-based solutions has led to groundbreaking research on nutraceutical therapies for IBD. Through international trials and prestigious awards, Salomon has garnered recognition for his pioneering work, culminating in the establishment of Evinature.
His dedication to bridging the gap between conventional medicine and herbal remedies underscores the ethos of the company, empowering patients with holistic treatment options.
Apan Amos Damri
Apan Amos Damri, the driving force behind Evinature’s entrepreneurial journey, brings a unique blend of vision and expertise to the table. As a seasoned entrepreneur and marketing maven, Damri’s journey from digital nomadism to founding leading marketing agencies speaks volumes about his tenacity and innovation. His quest for a project with a profound impact on society led him to Evinature, where he found resonance with the mission of promoting accessible and effective natural therapies for IBD.
With a passion for traditional medicine and a commitment to social responsibility, Damri’s leadership is instrumental in steering Evinature towards its goal of transforming healthcare on a global scale.
Together, Ben-Horin, Salomon, and Damri form the backbone of Evinature, and their collaborative efforts have not only revolutionized treatment protocols but have also catalyzed a paradigm shift in healthcare. As they continue to push the boundaries of integrative medicine, Evinature remains steadfast in its commitment to providing patients with personalized, evidence-based care.
